rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR T-cell therapy in solid tumors

Researchers tested a long-acting interleukin-7 with CAR T cells targeting glypican-2, glypican-3, and mesothelin in mouse models of solid tumors. The combination enhanced CAR T-cell expansion, reduced exhaustion, increased memory-like CAR T cells, and improved tumor control, including in tumors with low antigen density. The authors concluded that these results highlight the potential for the use of this combination in solid tumors in humans.